Stryker Co. (NYSE:SYK) is Stokes Capital Advisors LLC’s 5th Largest Position

Stokes Capital Advisors LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 1.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,388 shares of the medical technology company’s stock after purchasing an additional 261 shares during the period. Stryker makes up 2.7% of Stokes Capital Advisors LLC’s portfolio, making the stock its 5th largest holding. Stokes Capital Advisors LLC’s holdings in Stryker were worth $9,443,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Towerpoint Wealth LLC purchased a new stake in Stryker in the 1st quarter valued at about $238,000. Scharf Investments LLC boosted its position in Stryker by 8.6% in the 1st quarter. Scharf Investments LLC now owns 6,976 shares of the medical technology company’s stock valued at $2,497,000 after buying an additional 552 shares during the period. ERn Financial LLC boosted its position in Stryker by 1.0% in the 1st quarter. ERn Financial LLC now owns 4,649 shares of the medical technology company’s stock valued at $1,664,000 after buying an additional 44 shares during the period. Investment Partners Asset Management Inc. purchased a new stake in Stryker in the 1st quarter valued at about $234,000. Finally, Wealthcare Advisory Partners LLC boosted its position in Stryker by 41.4% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 1,049 shares of the medical technology company’s stock valued at $375,000 after buying an additional 307 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wells Fargo & Company boosted their price target on shares of Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Royal Bank of Canada boosted their price target on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. TD Cowen boosted their price target on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Evercore ISI boosted their price target on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Needham & Company LLC upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $392.00 price target for the company in a report on Wednesday, May 22nd. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $370.58.

Stryker Stock Performance

Shares of SYK stock traded down $0.62 during trading hours on Friday, hitting $339.92. The company’s stock had a trading volume of 172,795 shares, compared to its average volume of 1,301,811. The company has a 50 day moving average of $336.82 and a 200 day moving average of $333.01. The stock has a market cap of $129.49 billion, a PE ratio of 38.87, a price-to-earnings-growth ratio of 2.68 and a beta of 0.92. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.14 EPS. On average, sell-side analysts forecast that Stryker Co. will post 11.95 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.